Article Per Year (5 Year)
p-Index From 2019 - 2024
0.702
P-Index
This Author published in this journals
All Journal Ophthalmologica Indonesiana
Ajeng Kartika Ayu Putri
Unknown Affiliation
Health Professions Medicine & Pharmacology Public Health

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

 1 
Reducing Treatment Burden for Age-Related Macular Degeneration Patients: A Systematic Review of Ranibizumab Port Delivery System: Oral Presentation - Observational Study - General practitioner Dewa Ayu Anggi Paramitha; Ajeng Kartika Ayu Putri; Seruni Hanna Ardhia; Jovita Jutamulia
Majalah Oftalmologi Indonesia Vol 49 No S2 (2023): Supplement Edition
Publisher : The Indonesian Ophthalmologists Association (IOA, Perhimpunan Dokter Spesialis Mata Indonesia (Perdami))

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35749/v8vmp587

Abstract

Introduction & ObjectivesRanibizumab port delivery system (PDS) is a newly developed method that provides a continuous,long-term supply of ranibizumab into the vitreous, reducing the burden of monthly intravitrealinjection visits for neovascular age-related macular degeneration (nAMD) patients. This review aimsto evaluate the efficacy and safety of ranibizumab PDS in nAMD. MethodsAn extensive literature search was performed on 4 online databases: PubMed, Cochrane, ProQuest,and ScienceDirect. The inclusion criteria are human studies comparing ranibizumab port deliverysystem and intravitreal ranibizumab, English language, with full-text journal available. The mainoutcome measurements are best-corrected visual acuity (BCVA) in Early Treatment DiabeticRetinopathy Study (ETDRS) letters, central foveal thickness (CFT), and adverse events. ResultsTwo randomized controlled trials (RCTs) with a total of 638 adults were evaluated. At week 96,ranibizumab PDS reported observed mean BCVA changes from baseline (-1.0; +4.2; ETDRS letters)compared to monthly intravitreal ranibizumab (-1.1; +6.1; ETDRS letters). However, there was anincrease in mean CFT changes from baseline (+9.9; +22.3 vs ?1.3; ?35.8, ?m) and severe adverseevents frequency (22; 4 vs 4; 0) with ranibizumab PDS versus monthly intravitreal ranibizumab,respectively. ConclusionRanibizumab PDS showed comparable visual outcomes to intravitreal ranibizumab whiledemonstrating inferior anatomical outcomes and higher incidence of severe adverse effects. Despitethis, with fewer treatment visits required for up to 24 weeks, ranibizumab PDS can potentiallyreduce the treatment burden in nAMD patients with poor compliance. Further studies are needed toprovide better patient eligibility guidelines and recommendations for adverse event management ofranibizumab PDS.
Reducing Treatment Burden for Age-Related Macular Degeneration Patients: A Systematic Review of Ranibizumab Port Delivery System Dewa Ayu Anggi Paramitha; Ajeng Kartika Ayu Putri; Seruni Hanna Ardhia; Jovita Jutamulia
Majalah Oftalmologi Indonesia Vol 49 No S2 (2023): Supplement Edition
Publisher : The Indonesian Ophthalmologists Association (IOA, Perhimpunan Dokter Spesialis Mata Indonesia (Perdami))

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35749/zh73sh38

Abstract

Introduction & ObjectivesRanibizumab port delivery system (PDS) is a newly developed method that provides a continuous,long-term supply of ranibizumab into the vitreous, reducing the burden of monthly intravitrealinjection visits for neovascular age-related macular degeneration (nAMD) patients. This review aimsto evaluate the efficacy and safety of ranibizumab PDS in nAMD. MethodsAn extensive literature search was performed on 4 online databases: PubMed, Cochrane, ProQuest,and ScienceDirect. The inclusion criteria are human studies comparing ranibizumab port deliverysystem and intravitreal ranibizumab, English language, with full-text journal available. The mainoutcome measurements are best-corrected visual acuity (BCVA) in Early Treatment DiabeticRetinopathy Study (ETDRS) letters, central foveal thickness (CFT), and adverse events. ResultsTwo randomized controlled trials (RCTs) with a total of 638 adults were evaluated. At week 96,ranibizumab PDS reported observed mean BCVA changes from baseline (-1.0; +4.2; ETDRS letters)compared to monthly intravitreal ranibizumab (-1.1; +6.1; ETDRS letters). However, there was anincrease in mean CFT changes from baseline (+9.9; +22.3 vs ?1.3; ?35.8, ?m) and severe adverseevents frequency (22; 4 vs 4; 0) with ranibizumab PDS versus monthly intravitreal ranibizumab,respectively. ConclusionRanibizumab PDS showed comparable visual outcomes to intravitreal ranibizumab whiledemonstrating inferior anatomical outcomes and higher incidence of severe adverse effects. Despitethis, with fewer treatment visits required for up to 24 weeks, ranibizumab PDS can potentiallyreduce the treatment burden in nAMD patients with poor compliance. Further studies are needed toprovide better patient eligibility guidelines and recommendations for adverse event management ofranibizumab PDS.
Efficacy and safety of Orthokeratology in Moderate and High Myopia Patients at Vio Optical Clinic During Januari 2020- December 2022 : A Retrospective Study: Poster Presentation - Observational Research - Ophthalmologist WENI PUSPITASARI; Ajeng Kartika Ayu Putri
Majalah Oftalmologi Indonesia Vol 49 No S2 (2023): Supplement Edition
Publisher : The Indonesian Ophthalmologists Association (IOA, Perhimpunan Dokter Spesialis Mata Indonesia (Perdami))

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35749/7k210520

Abstract

Introduction & Objectives : Orthokeratology (OK) lens causes flattening of the cornea to reduce refractive power temporarily. The purpose of the current study was to determine efficacy, defined in terms of refractive correction, and common adverse effects in Indonesian population. Methods : Objective: To evaluate the efficacy and safety of OK for myopia correction and visual acuity (VA) changes in moderate and high myopia patients at Vio Optical Clinic Grand Galaxy Bekasi during January 2020 – December 2022 Results : Methods: In this retrospective study, 129 eyes with moderate and high myopia met the inclusion criteria of this study. Each subject wore the lens for 8 to 9 hours while asleep. The efficacy and safety were assessed after 1, 4, and 12 weeks follow up. Result: All subjects divided into two groups: 106 eyes (82.2%) had moderate myopia and 23 eyes (17.8%) had high myopia. The median age was 18 years old (ranging from 5 - 45 years). The spherical equivalent of VA of two groups decreased significantly in 1 and 4 weeks compare to pre-lens (p<0.001). LogMar uncorrected visual acuity (UCVA) of two groups showed improvement in 1 and 4 weeks compare to pre-lens (p<0.001). There were no severe complication in moderate myopia patients. There were three subjects of corneal staining were recorded in high myopia Conclusion : This study indicates orthokeratology is a safe and effective to correct myopia. Using orthokeratology can improve UCVA within one week and one month after OK lens in moderate and high myopia patients. There were mild complication in high myopia patients.
Orthokeratology fitting in a Post LASIK Patients : A Case Report: Poster Presentation - Case Report - Ophthalmologist WENI PUSPITASARI; Ajeng Kartika Ayu Putri
Majalah Oftalmologi Indonesia Vol 49 No S2 (2023): Supplement Edition
Publisher : The Indonesian Ophthalmologists Association (IOA, Perhimpunan Dokter Spesialis Mata Indonesia (Perdami))

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35749/291hbb39

Abstract

Introduction : Refractive surgery patients may have residual refractive eror.. Orthokeratology (OK) lenses are a less common option for correcting refractive eror in post refractive surgery patients. This case discusses OK lens as an alternative to LASIK enhancement, patient selection and fitting. Case Illustration : A 34 years old male complaint of blurred vision in both eye . He presented to our clinic with a refraction in the right eye (RE) of S -2.50 cyl -1.25 x 90 and in the the left eye (LE) of S -2.5.00 cyl -1.00 x 80. He underwent bilateral LASIK surgery 10 years ago with recalled refraction of approximately –6.00D in both eyes. Following one week of lens wear, the residual refraction of RE ?1.50 ?0.50 x 90 and LE ?1.50 ?0.50 x 80. After one month,the refraction in RE ?1.00 ?0.50 x 90 and LE ?1.00 ?0.25 x 80. Following a six months, the refraction of RE was -1.00 cyl?0.25 x 90 and-1.00 cyl -0.25x 80 in the LE. He is well satisfied with the level of uncorrected vision throughout the day Discussion : OK lenses are could be an alternative to LASIK enhancement. The good candidate for post refractive surgery in OK, there were no significant corneal irregularity, BCVA 20/20, and K’s reading between 40-46. It is recommended to wait at least 1 year post Lasik before fitting OK lenses and the process may take longer due to oblate cornea. Conclusion : OK lenses are effective alternative to LASIK enhancement. Proper patients selection are vital to achieve a satisfied patient.
Co-Authors Dewa Ayu Anggi Paramitha Jovita Jutamulia Seruni Hanna Ardhia WENI PUSPITASARI